Table 23:

Scenario Analysis Results, Results From a Cochrane Systematic Review on NIPT Test Accuracy

Strategy	Total Costs (95% CrI), $	Cases Detected (95% CrI), n	Diagnostic Tests Performed (95% CrI), n	Diagnostic-Procedure-Related Pregnancy Losses (95% CrI), n	Affected Live Births (95% CrI), n	Incremental Cost Per Case Detected, vs. Second-Tier NIPT, $
Second-tier NIPT	26,649,544 (23,187,889–29,795,150)	All: 189 (148–236) Trisomy 21: 148 (112–195) Trisomy 18: 41 (23–64) Trisomy 13: 0 (0–1)	659 (584–742)	1 (0–3)	All: 177 (150–204) Trisomy 21: 132 (109–155) Trisomy 18: 25 (15–35) Trisomy 13: 21 (12–31)	—
First-tier NIPT	59,674,614 (51,919,853–67,932,570)	All: 269 (215–331) Trisomy 21: 192 (150–246) Trisomy 18: 62 (37–94) Trisomy 13: 15 (5–31)	572 (442–710)	1 (0–3)	All: 148 (124–173) Trisomy 21: 112 (91–134) Trisomy 18: 20 (12–30) Trisomy 13: 15 (8–24)	412,010

Abbreviations: CrI, credible interval; NIPT, noninvasive prenatal testing.

Note: Numbers may appear inexact due to rounding.